Peptide-based therapeutic vaccines for allergic and autoimmune diseases

Nature Medicine

Volumn 11, Issue 4S, 2005, Pages S69-

  Larché, Mark ^a   Wraith, David C ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

API M 1 ANTIGEN; FEL D 1 ANTIGEN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 60; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; MYELIN BASIC PROTEIN; PEPTIDE; PHOSPHOLIPASE A2; PROTEIN DNAJ; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VACCINE;

ALLERGIC DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BYSTANDER EFFECT; CYTOKINE RELEASE; DANDER; DESENSITIZATION; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MUCOSAL IMMUNITY; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; ANTIGENS; AUTOIMMUNE DISEASES; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; VACCINATION; VACCINES, SUBUNIT;

ANIMALIA;

EID: 17644401678     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1226     Document Type: Article

References (128)

1. Cookson, W. Genetics and genomics of asthma and allergic diseases. Immunol. Rev. 190, 195-206 (2002).
2. Merriman, T.R. & Todd, J.A. Genetics of autoimmune disease. Curr. Opin. Immunol. 7, 786-792 (1995).
3. Sawcer, S. et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p2l and i/q22. Nat. Genet. 13, 464-468 (1996).
4. Bali, D. et al. Genetic analysis of multiplex rheumatoid arthritis families. Genes Immun. 1, 28-36 (1999).
5. Strachan, D.P. Hay fever, hygiene, and household size. Br. Med. J. 299, 1259-1260 (1989).
6. Gale, E.A. A missing link in the hygiene hypothesis? Diabetologia 45, 588-594 (2002).
7. Heaton, T. et al. An immunoepidemiological approach to asthma: Identification of in vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet 365, 142-149 (2005).
8. Hansen, G., Berry, G., DeKruyff, R.H. & Umetsu, D. T. Allergen-specific Th1 cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. J. Clin. Invest. 103, 175-183 (1999).
9. Lafaille, J.J. et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186, 307-312 (1997).
10. Barthlott, T., Kassiotis, G. & Stockinger, B. T cell regulation as a side effect of homeostasis and competition. J. Exp. Med. 197, 451-460 (2003).
11. Bach, J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347, 911-920 (2002).
12. Wraith, D.C., Nicolson, K.S. & Whitley, N.T. Regulatory CD4(+) T cells and the control of autoimmune disease. Curr. Opin. Immunol. 16, 695-701 (2004).
13. Ling, E.M. et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen- driven T-cell activation to atopic status and expression of allergic disease. Lancet 363, 608-615 (2004).
14. Cavani, A. et al. Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J. Immunol. 171, 5760-5768 (2003).
15. Karlsson, M.R., Rugtveit, J. & Brandtzaeg, P. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow’s milk allergy. J. Exp. Med. 199, 1679-1688 (2004).
16. Ou, L.S., Goleva, E., Hall, C. & Leung, D.Y. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J. Allergy Clin. Immunol. 113, 756-763 (2004).
17. Balandina, A., Lecart, S., Dartevelle, P., Saoudi, A. & Berrih-Aknin, S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105, 735-741 (2005).
18. de Kleer, I.M. et al. CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J. Immunol. 172, 6435-6443 (2004).
19. Arif, S. et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113, 451-463 (2004).
20. Viglietta, V., Baecher-Allan, C., Weiner, H.L. & Hafler, D.A. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199, 971-979 (2004).
21. Barrett, J.H., Brennan, P., Fiddler, M. & Silman, A.J. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum. 42, 1219-1227 (1999).
22. Platts-Mills, T., Vaughan, J., Squillace, S., Woodfolk, J. & Sporik, R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: A population-based cross-sectional study. Lancet 357, 752-756 (2001).
23. Durham, S.R. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341, 468-475 (1999).
24. Bousquet, J. et al. Allergen immunotherapy: Therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 81, 401-405 (1998).
25. Noon, L. Prophylactic innoculation against hay fever. Lancet i, 1572-1573 (1911).
26. Ebner, C. et al. Immunological changes during specific immunotherapy of grass pollen allergy: Reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy 27, 1007-1015 (1997).
27. Secrist, H., Chelen, C.J., Wen, Y., Marshall, J.D. & Umetsu, D.T. Allergen immuno- therapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J. Exp. Med. 178, 2123-2130 (1993).
28. Varney, V.A. et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. 92, 644-651 (1993).
29. Wachholz, P.A. et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios. Immunology 105, 56-62 (2002).
30. Francis, J.N., Till, S.J. & Durham, S.R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol. 111, 1255-1261 (2003).
31. Jutel, M. et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur. J. Immunol. 33, 1205-1214 (2003).
32. Nouri-Aria, K.T. et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol. 172, 3252-3259 (2004).
33. Nasser, S.M., Ying, S., Meng, Q., Kay, A.B. & Ewan, P.W. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur. J. Immunol. 31, 3704-3713 (2001).
34. Burkhart, C., Liu, G.Y., Anderton, S.M., Metzler, B. & Wraith, D.C. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: A role for IL-10. Int. Immunol. 11, 1625-1634 (1999).
35. Sundstedt, A., O’Neill, E. J., Nicolson, K. S. & Wraith, D. C. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J. Immunol. 170, 1240-1248 (2003).
36. Barrat, F.J. et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195, 603-616 (2002).
37. Mathisen, P.M., Yu, M., Johnson, J.M., Drazba, J.A. & Tuohy, V.K. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J. Exp. Med. 186, 159-164 (1997).
38. Akdis, C.A. et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 98, 16761683 (1996).
39. Akdis, C.A., Blesken, T., Akdis, M., Wuthrich, B. & Blaser, K. Role of interleukin 10 in specific immunotherapy. J. Clin. Invest 102, 98-106 (1998).
40. Jeannin, P., Lecoanet, S., Delneste, Y., Gauchat, J.F. & Bonnefoy, J.Y. IgE versus IgG4 production can be differentially regulated by IL-10. J. Immunol. 160, 3555-3561 (1998).
41. Galli, S.J., Nakae, S. & Tsai, M. Mast cells in the development of adaptive immune responses. Nat. Immunol. 6, 135-142 (2005).
42. Pedotti, R., De Voss, J.J., Steinman, L. & Galli, S.J. Involvement of both ’allergic’ and ’autoimmune’ mechanisms in EAE, MS and other autoimmune diseases. Trends Immunol. 24, 479-484 (2003).
43. Liblau, R.S., Singer, S.M. & McDevitt, H.O. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol. Today 16, 34-38 (1995).
44. Duda, P.W., Schmied, M.C., Cook, S.L., Krieger, J.I. & Hafler, D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105, 967-976 (2000).
45. Munari, L., Lovati, R. & Boiko, A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst. Rev. CD004678 (2004).
46. Johnson, K.P. et al. Glatiramer acetate (Copaxone): Comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult. Scler. 9, 585-591 (2003).
47. Johnson, K.P., Ford, C.C., Lisak, R.P. & Wolinsky, J.S. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol. Scand. 111, 42-47 (2005).
48. Stern, J.N. et al. Amelioration of proteolipid protein 139-151-induced encephalomy- elitis in SJL mice by modified amino acid copolymers and their mechanisms. Proc. Natl. Acad. Sci. USA 101, 11743-11748 (2004).
49. Stern, J.N. et al. Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomy- elitis. Proc. Natl. Acad. Sci. USA 102, 1620-1625 (2005).
50. Faria, A.M. & Weiner, H.L. Oral tolerance: Mechanisms and therapeutic applications. Adv. Immunol. 73, 153-264 (1999).
51. Dakin, R. Remarks on a cutaneous affection produced by certain poisonous vegetables. Am. J. Med. Sci. 4, 98-100 (1829).
52. Weiner, H.L. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases. Immunol. Today 18, 335-343 (1997).
53. Nussenblatt, R.B. et al. Treatment of uveitis by oral administration of retinal antigens: Results of a phase I/II randomized masked trial. Am. J. Ophthalmol. 123, 583-592 (1997).
54. Sun, J.B., Rask, C., Olsson, T., Holmgren, J. & Czerkinsky, C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl. Acad. Sci. USA 93, 7196-7201 (1996).
55. Williams, N.A., Hirst, T.R., & Nashar, T.O. Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic. Immunol. Today20, 95-101 (1999).
56. Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., & Weiner, H.L. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 265, 1237-1240 (1994).
57. Maron, R., Melican, N.S., & Weiner, H.L. Regulatory Th2-type T cell lines against insulin and GAD peptides derived from orally- and nasally-treated NOD mice suppress diabetes. J. Autoimmun. 12, 251-258 (1999).
58. al Sabbagh, A., Nelson, P.A., Akselband, Y., Sobel, R.A., & Weiner, H.L. Antigen- driven peripheral immune tolerance: Suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. Cell. Immunol. 171, 111-119 (1996).
59. Anderton, S.M., Burkhart, C., Liu, G.Y., Metzler, B. & Wraith, D. C. Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease. Novartis Found. Symp. 215, 120-131 (1998).
60. Alpan, O., Bachelder, E., Isil, E., Arnheiter, H. & Matzinger, P. ’Educated’ dendritic cells act as messengers from memory to naive T helper cells. Nat. Immunol 5, 615-622 (2004).
61. Lehmann, P.V., Forsthuber, T., Miller, A. & Sercarz, E.E. Spreading of T-cell autoim- munity to cryptic determinants of an autoantigen. Nature 358, 155-157 (1992).
62. Genain, C. P. et al. Late complications of immune deviation therapy in a nonhuman primate. Science 274, 2054-2057 (1996).
63. Blanas, E., Carbone, F.R., Allison, J., Miller, J.F. & Heath, W.R. Induction of autoimmune diabetes by oral administration of autoantigen. Science 274, 1707-1709 (1996).
64. Hanninen, A., Braakhuis, A., Heath, W. R., & Harrison, L. C. Mucosal antigen primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery route. Diabetes 50, 771-775 (2001).
65. Norman, P.S., Lichtenstein, L.M., & Marsh, D.G. Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J. Allergy Clin. Immunol. 68, 460-470 (1981).
66. Niederberger, V. et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA 101 Suppl 2, 14677-14682 (2004).
67. Valenta, R. et al. Genetically engineered and synthetic allergen derivatives: Candidates for vaccination against type I allergy. Biol. Chem. 380, 815-824 (1999).
68. Hoyne, G.F., O’Hehir, R.E., Wraith, D.C., Thomas, W.R., & Lamb, J.R. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 178, 1783-1788 (1993).
69. Briner, T. J., Kuo, M. C., Keating, K. M., Rogers, B. L. & Greenstein, J. L. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc. Natl. Acad. Sci. USA 90, 7608-7612 (1993).
70. Norman, P.S. et al. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 154, 1623-1628 (1996).
71. Maguire, P., Nicodemus, C., Robinson, D., Aaronson, D. & Umetsu, D.T. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin. Immunol. 93, 222-231 (1999).
72. Simons, F.E., Imada, M., Li, Y., Watson, W.T., & HayGlass, K.T. Fel d 1 peptides: Effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int. Immunol. 8, 1937-1945 (1996).
73. Pene, J. et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J. Allergy Clin. Immunol. 102, 571-578 (1998).
74. Muller, U. et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101, 747-754 (1998).
75. Fellrath, J.M. et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: Results of a phase I trial. J. Allergy Clin. Immunol. 111, 854-861 (2003).
76. Oldfield, W.L., Kay, A.B. & Larche, M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol. 167, 1734-1739 (2001).
77. Oldfield, W.L., Larche, M. & Kay, A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: A randomised controlled trial. Lancet 360, 47-53 (2002).
78. Alexander, C., Tarzi, M., Larche, M. & Kay, A. B. The effect of Fel d 1-derived T cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy, in the press.
79. Alexander, C., Ying, S., Kay, B. & Larche, M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4CD25; CD4 interferon-gamma T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin. Exp. Allergy 35, 52-58 (2005).
80. Metzler, B. & Wraith, D.C. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity. Int. Immunol 5, 1159-1165 (1993).
81. Anderton, S.M. & Wraith, D.C. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur. J. Immunol 28, 1251-1261 (1998).
82. Liu, J.Q. et al. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: Synergistic effects of MBP 68-86 and 87-99. Int. Immunol. 10, 1139-1148 (1998).
83. Staines, N.A. et al. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol. 103, 368-375 (1996).
84. Chu, C.Q. & Londei, M. Differential activities of immunogenic collagen type II pep- tides in the induction of nasal tolerance to collagen-induced arthritis. J. Autoimmun. 12, 35-42 (1999).
85. Prakken, B.J. et al. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobi- ally induced experimental arthritis. Proc. Natl. Acad. Sci. USA 94, 3284-3289 (1997).
86. Tian, J. et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183, 1561-1567 (1996).
87. Daniel, D. & Wegmann, D. R. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA 93, 956-960 (1996).
88. Elias, D. et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 46, 758-764 (1997).
89. Thurau, S.R., Chan, C.C., Suh, E. & Nussenblatt, RB. Induction of oral tolerance to S-antigen induced experimental autoimmune uveitis by a uveitogenic 20mer peptide. J. Autoimmun. 4, 507-516 (1991).
90. Karachunski, P.I., Ostlie, N.S., Okita, D.K. & Conti-Fine, B.M. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest 100, 3027-3035 (1997).
91. Paas-Rozner, M. et al. Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice. Proc. Natl. Acad. Sci. USA 97, 2168-2173 (2000).
92. Zou, L.P. et al. Antigen-specific immunosuppression: Nasal tolerance to P0 protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats. J. Neuroimmunol. 94, 109-121 (1999).
93. Raz, I. et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 358, 1749-1753 (2001).
94. Prakken, B.J. et al. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 101, 4228-4233 (2004).
95. Sloan-Lancaster, J. & Allen, P. M. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology. Annu.Rev.Immunol 14, 1-27 (1996).
96. Franco, A. et al. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur. J. Immunol. 24, 940-946 (1994).
97. Karin, N., Mitchell, D.J., Brocke, S., Ling, N. & Steinman, L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J. Exp. Med. 180, 2227-2237 (1994).
98. Kuchroo, V.K. et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 153, 3326-3336 (1994).
99. Nicholson, L.B., Murtaza, A., Hafler, B.P., Sette, A. & Kuchroo, V.K. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc. Natl. Acad. Sci. USA 94, 9279-9284 (1997).
100. Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in relapsing MS Study Group. Nat. Med. 6, 1176-1182 (2000).
101. Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6, 1167-1175 (2000).
102. Anderton, S.M., Manickasingham, S.P. & Wraith, D.C. Fine specificity of myelin basic protein reactive T-cells: Implications for T-cell receptor antagonism. Biochem. Soc. Trans. 25, 659-661 (1997).
103. Chai, J.G., James, E., Dewchand, H., Simpson, E. & Scott, D. Transplantation tolerance induced by intranasal administration of HY peptides. Blood 103, 3951-3959 (2004).
104. Kearney, E.R., Pape, K.A., Loh, D.Y. & Jenkins, M.K. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1, 327-339 (1994).
105. Critchfield, J. M. et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263, 1139-1143 (1994).
106. Paas-Rozner, M., Sela, M., & Mozes, E. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes. Proc. Natl. Acad. Sci. USA 98, 12642-12647 (2001).
107. Apostolou, I. & Von Boehmer, H. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199, 1401-1408 (2004).
108. Verhoef, A., Alexander, C., Kay, A.B. & Larche, M. T Cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med., in the press.
109. Haselden, B.M., Kay, A.B., & Larche, M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189, 1885-1894 (1999).
110. Vidard, L., Colarusso, L.J., & Benacerraf, B. Specific T-cell tolerance may be preceded by a primary response. Proc. Natl. Acad. Sci. USA 91, 5627-5631 (1994).
111. Webb, S., Morris, C. & Sprent, J. Extrathymic tolerance of mature T cells: Clonal elimination as a consequence of immunity. Cell 63, 1249-1256 (1990).
112. Hoyne, G.F., Askonas, B.A., Hetzel, C., Thomas, W.R., & Lamb, J.R. Regulation of house dust mite responses by intranasally administered peptide: Transient activation of CD4+ T cells precedes the development of tolerance in vivo. Int. Immunol. 8, 335-342 (1996).
113. Ali, F.R., Oldfield, W.L., Higashi, N., Larche, M. & Kay, A. B. Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides. Am. J. Respir. Crit. Care Med. 169, 20-26 (2004).
114. Metzler, B., Anderton, S.M., Manickasingham, S.P., & Wraith, D.C. Kinetics of peptide uptake and tissue distribution following a single intranasal dose of peptide. Immunol. Invest. 29, 61-70 (2000).
115. Arentz-Hansen, H. et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J. Exp. Med. 191, 603-612 (2000).
116. Martin, R., McFarland, H.F. & McFarlin, D.E. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol 10, 153-187 (1992).
117. Southwood, S. et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. J. Immunol. 160, 3363-3373 (1998).
118. Texier, C. et al. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164, 3177-3184 (2000).
119. Anderton, S.M., Viner, N.J., Matharu, P., Lowrey, P.A. & Wraith, D.C. Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat. Immunol 3, 175-181 (2002).
120. Shen, C.R. et al. Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. Blood 102, 3800-3806 (2003).
121. Santambrogio, L., Sato, A.K., Fischer, F.R., Dorf, M.E. & Stern, L.J. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc. Natl. Acad. Sci. USA 96, 15050-15055 (1999).
122. Jonuleit, H., Schmitt, E., Schuler, G., Knop, J. & Enk, A. H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192, 1213-1222 (2000).
123. Wakkach, A. et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18, 605-617 (2003).
124. Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen- specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).
125. Menges, M. et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 195, 15-21 (2002).
126. Zamvil, S.S. et al. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 324, 258-260 (1986).
127. Liu, G.Y. & Wraith, D.C. Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult mice-implications for autoimmunity. Int. Immunol. 7, 1255-1263 (1995).
128. Metzler, B. & Wraith, D.C. Inhibition of T-cell responsiveness by nasal peptide administration: Influence of the thymus and differential recovery of T-cell-dependent functions. Immunology 97, 257-263 (1999).